Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
[google_news title=”” keyword=”macular degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Prevent Blindness Declares Third Annual Geographic Atrophy Awareness Weekon December 1, 2023 at 3:45 am
Prevent Blindness provides free geographic atrophy educational resources for patients, care partners and healthcare professionals.
- Dr. Caruso: Are You at Risk for Macular Degeneration?on November 30, 2023 at 12:45 pm
If you’re over 65 and of European descent, you could be at risk for macular degeneration, the leading cause of age-related vision loss. Yet lifestyle choices can help to slow the disease’s progression ...
- Eat This Unexpected Protein To Improve Your Eye Healthon November 30, 2023 at 4:30 am
The body requires certain nutrients for good eye health. Here's a surprising protein-rich food (commonly associated with gut health) that's good for your eyes.
- Ocutrx Technologies' OcuLenz: A new augmented reality headset to enhance the visual clarity for patients who have advanced macular degenerationson November 30, 2023 at 3:00 am
The augmented reality headset compensates for central vision loss to enhance the visual clarity of patients with age-related macular degeneration and other conditions such as Stargardt disease.
- Dr. ROACH: Vitamins for macular degeneration coincide with new crampson November 29, 2023 at 9:41 am
I have been told at the age of 70 that I am in the early stages of the eye disease macular degeneration. The doctor told me to take PreserVision AREDS 2 vitamins. He said that I ...
- RetinAI Medical joins non-profit macular degeneration initiativeon November 29, 2023 at 7:37 am
RetinAI Medical, a Swiss developer of software for accelerating retinal disease R&D, has joined the Ryan Initiative for Macular Research, a non-profit consortium working on defining optimal biomarkers ...
- InMed Pharmaceuticals (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular Degenerationon November 29, 2023 at 6:48 am
Detailed price information for Adv Micro Devices (AMD-Q) from The Globe and Mail including charting and trades.
- InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degenerationon November 29, 2023 at 5:00 am
INM-089 improves retinal function in in vivo preclinical AMD disease modelEstablishes cannabinol (CBN) analog candidate in a new disease targetVancouver, British Columbia--(Newsfile Corp. - November ...
- OcuLenz headset to provide those with advanced macular degeneration with enhanced visual clarityon November 29, 2023 at 2:59 am
The augmented reality headset compensates for central vision loss to enhance the visual clarity of patients with age-related macular degeneration and other conditions such as Stargardt disease. Ocutrx ...
- Wet Age-Related Macular Degeneration Drug Pipeline Research Report 2023on November 28, 2023 at 4:33 am
The "Wet Age-Related Macular Degeneration - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This "Wet Age-related Macular Degeneration - Pipeline Insight, ...
via Google News and Bing News